Skip to main content
Explore URMC

Wilmot Cancer Institute Logo

Clive S. Zent, M.D.
Clive S. Zent, M.D.

Clive S. Zent, M.D.

Medicine — Hematology/Oncology — Hematology

Accepting New Patients

Clive S. Zent, M.D.

Medicine — Hematology/Oncology — Hematology

Accepting New Patients


James P. Wilmot Cancer Center
601 Elmwood Ave.
Rochester, NY 14642
Get Directions



(585) 275-5823



(585) 273-1042

About Me

I chose this specialty because I have always had an interest in diseases of the blood. My patients can be confident knowing I provide optimal individual patient care based on precision diagnosis and targeted therapy. Although I treat many types of blood diseases, my area of expertise is chronic lymphocytic leukemia.

Conditions I Treat:

- Chronic lymphocytic leukemia/Small lymphocytic lymphoma (CLL)
- Hairy cell leukemia
- Prolymphocytic leukemia
- Lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia)
- Large granular lymphocytic leukemia



MB Bchir | University of Witwatersrand — 1983

Post-doctoral Training & Residency:

Internship in Internal Medicine at University of Witwatersrand — 1984 - 1984
Residency in Internal Medicine at Groote Schuur Hospital - University of Cape Town — 1987 - 1991
Residency in Internal Medicine at University of Arkansas College of Medicine — 1996 - 1997
Fellowship in Hematology at University of Chicago Medical Center — 1993 - 1996


Dr. Clive Zent is a highly experienced hematologist and internationally recognized researcher and expert in the care of patients with chronic lymphocytic leukemia (CLL) and related lymphoid malignancies. While training in Hematology at the University of Chicago, Dr. Zent studied the molecular genetics of hematological malignancies in the laboratory of Dr. Janet Rowley. His clinical and research interest in CLL started as an attending physician at the Central Arkansas Veterans Healthcare System and continued when he joined the staff of the Mayo Clinic in Rochester MN in 2003. In 2013 he was appointed to the faculty of the Wilmot Cancer Center at the University of Rochester Medical Center as Professor of Medicine and director of the Chronic Lymphocytic Leukemia program.

Dr. Zent's research has improved our understanding of the therapeutic monoclonal antibodies used to treat CLL, use of molecular prognostic markers in the management of CLL, diagnosis of CLL and related diseases, and evaluation and management of autoimmune cytopenias and second malignancies complicating CLL. His goal as a clinician, researcher and teacher is to continue to improve treatment and outcome for patients with CLL.


Helber MJ, Moore JE, Williams AM, Meacham PJ, Rothberg PG, Zent CS. "Ibrutinib therapy for lymphoplasmacytic lymphoma." American journal of hematology.. 2017 Sep 0; 92(9):E542-E544. Epub 2017 Jun 09.

Taylor RP, Lindorfer MA, Cook EM, Beurskens FJ, Schuurman J, Parren PWHI, Zent CS, VanDerMeid KR, Burack R, Mizuno M, Paul Morgan B. "Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9." Clinical immunology : the official journal of the Clinical Immunology Society.. 2017 Aug 0; 181:24-28. Epub 2017 May 31.

Williams AM, Baran AM, Meacham PJ, Feldman MM, Valencia HE, Newsom-Stewart C, Gupta N, Janelsins MC, Barr PM, Zent CS. "Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies." Leukemia & lymphoma.. 2017 Jul 11; :1-8. Epub 2017 Jul 11.

View All Publications